Wolfe Research analyst Darrin Peller initiates coverage on Toast (NYSE:TOST) with a Peer Perform rating.
Why Adaptimmune Therapeutics (ADAP) Stock Is Moving
Adaptimmune Therapeutics shares are trading higher by 15.8% during Friday's session. The company and Galapagos entered a clinical collaboration.